Never heard of it before.... ***************************
PERSANTINE® Boehringer Ingelheim Dipyridamole Coronary Vasodilator - Inhibitor of Platelet Adhesion and Aggregation
Action And Clinical Pharmacology: Dipyridamole normalizes increased platelet adhesiveness and tendency to aggregate (Hellem's method). Dipyridamole has been found to lengthen abnormally shortened platelet survival time in a dose-dependent manner; 400 mg/day or 100 mg/day plus 1 g ASA.
It is believed that platelet reactivity and interaction with prosthetic cardiac valve surfaces, resulting in abnormal shortened platelet survival time is a significant factor in connection with prosthetic heart valve replacement.
In a controlled clinical trial involving patients who had undergone surgical placement of prosthetic heart valves (mitral and/or aortic valve replacement), Persantine, in combination with anticoagulants, significantly decreased the incidence of post-operative thromboembolic events, without increasing hemorrhagic complications. The incidence of thromboembolic events in patients receiving dipyridamole in a dose of 400 mg/day in combination with anticoagulants was 1.3% compared to 14.3% to the control group treated with anticoagulant alone.